Navigation Links
Inovio's Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
Date:6/14/2013

w rapidly we can create a DNA vaccine construct to address a new global threat." 

In the preclinical study Inovio researchers constructed a consensus DNA vaccine targeting the HA influenza antigen from sequences collected from several infected H7N9 patients to be broadly protective against all H7N9 viruses. The vaccine was designed, optimized, and manufactured within two weeks, and mice were immunized intramuscularly with two doses followed by electroporation three weeks apart. In an interim analysis, researchers tested sera from the animals against an unmatched H7N9 influenza strain, A/Anhui/1/13. The researchers observed levels of HAI titers, or functional antibodies, that predict protection against the H7N9 virus as well as robust levels of binding antibodies which can block virus entry into host cells as well as inhibit other viral functions.

Generating these very strong immune responses against an unmatched influenza strain adds further to the growing data set indicating the universal protective capability that Inovio's SynCon® DNA vaccines are able to achieve within targeted subtypes. While this study demonstrates that Inovio can respond to an urgent need to address a new subtype of influenza, it also provides further validation of its approach to address the more important need of providing truly preemptive and broad long-term protection against the constant strain mutations that occur within influenza subtypes. The ideal outcome would be to achieve a universal influenza vaccine capable of broad protection against existing and newly emergent unmatched strains across subtypes known to threaten humans.

Using our synthetic consensus design approach, we have created DNA "constructs" for key virus clades (branches) within the Type A subtypes H1N1, H2N2, H3N2, and H5N1 as well as Type B, and target multiple influenza antigens associated with influenza, including the most frequently changing antigen, HA. We c
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Finesse Solutions Launches Next Generation G3Lab Universal SmartControllers to Enhance Productivity in Bench Scale Cell Culture and Fermentation
2. Flexpoint Announces Universal Settlement Involving the Medical Bed and Related Technologies
3. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
5. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. ASCO Interview of MD Andersons Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites
8. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
9. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
10. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
11. Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Denovo Biopharma, LLC, ... late-stage oncology drug, from Eli Lilly and Company ... manufacture and commercialize enzastaurin globally, including transfer of ... information. Lilly developed enzastaurin in ... and Phase 3 clinical trials for diffuse large ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 2
... Pressure and Triglycerides Also Observed , , NEW ORLEANS, ... ), Eli Lilly and Company (NYSE: LLY ), ... long-term, interim results from the DURATION-1 study that showed sustained ... systolic blood pressure and triglycerides, through two years of treatment ...
... June 7 New Phase II data presented today at ... show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) ... weekly, biweekly and monthly dosing. Reducing blood sugar is ... that affects over 250 million people worldwide. , ...
Cached Medicine Technology:Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 2Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 3Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 4Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 5Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 6Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009 7Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 2Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight 3
(Date:9/17/2014)... Irvington, NY (PRWEB) September 17, 2014 ... youth sports, concussion prevention is top of mind ... developed five facts to remember about concussions and ... Treatment, developed for kids, parents, coaches and teachers ... , "As a pediatric orthopedic ...
(Date:9/17/2014)... Lee Berman, a seasoned veteran of ... on The Balancing Act® airing on Lifetime Television®. Berman ... segment will premiere on September 19 and re-air on ... on Lifetime Television®' with show host Julie Moran. Berman ... over a decade and is the Director of Marketing ...
(Date:9/17/2014)... Freeslate, Inc. , the leading ... development, today announced that Baylor University acquired a ... to both support Baylor research interests and provide ... throughput system is expected to significantly accelerate innovation ... for small molecule organic chemistry. , The ...
(Date:9/17/2014)... Presence Technology, a multinational provider ... Suite 10.0, which incorporates significant enhancements to meet ... , The Contact Center Agents and Supervisors will ... get a better feel for the performance of ... and who requires additional coaching or mentoring to ...
(Date:9/16/2014)... BamboofloorChina.com, the popular online supplier of elegant bamboo items, ... bamboo floors to its product catalogue. Along with ... new items; the current discount is up to 27 ... season. Therefore, BamboofloorChina.com spares no energy to offer more ... items offered by BamboofloorChina.com are in stock and ready ...
Breaking Medicine News(10 mins):Health News:Video Helps Kids and Adults Talk About Concussion Recognition and Treatment 2Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2
... VIEJO, Calif., Sept. 19 Clarient, Inc.,(Nasdaq: CLRT ... and the pharmaceutical industry, today announced,that it is scheduled ... Life Sciences Conference at 4:30 p.m. EDT on Wednesday, ... Grand Hyatt in New York City,September 24-27. A ...
... /Xinhua-PRNewswire-FirstCall/ -- To help buyers,identify suppliers offering ... GSOL ) and Bureau Veritas, one ... have launched the B2B industry,s,most comprehensive supplier ... ) Co-developed by the two companies, ...
... volunteers representing the Women,s Dermatologic Society (WDS) will, help ... free skin cancer screenings and sun safety ... PLANO, Texas, Sept. 18 Even though higher altitudes,mean ... balloon,enthusiasts enjoying the upcoming Plano Hot Air Balloon Festival ...
... following statement today on proposed legislation by Senators,Kent Conrad ... to create a,task force to reform Social Security and ... the most successful safety,nets in our nation and any ... be done by the committees of jurisdiction in Congress; ...
... and other tissue in the laboratory in conditions similar to ... The technology, developed and patented by scientists at Durham University ... which allows cells to be grown in a more realistic ... a Petri dish. , Evidence gathered by the research ...
... ELMHURST, Ill., Sept. 18 Secure Services Corp. ... Parke has joined,them as the Director of Business ... northwest suburbs for 22 years. He was an,acknowledged ... of the National Conference of Insurance Legislators (NCOIL). ...
Cached Medicine News:Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 3Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 4Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 2Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 3Health News:Cell growth technology promises more successful drug development 2Health News:Cell growth technology promises more successful drug development 3Health News:Former State Representative Terry Parke Joins Secure Services Corp. 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: